- Home >
- Life Sciences >
- Pharmaceutical >
- Therapy >
Therapy Industry Analysis and Statistics (since 2008 - p2)
All premium reports for Therapy Industry Analysis and Statistics (since 2008 - p2)
31-60 of 150 Premium Reports from 16 Publishers
Amgen Inc. - SWOT Analysis
- $ 125
- July 2009
Datamonitor's Amgen Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. Amgen Inc. - SWOT Analysis examines the company?s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strat ...
Industries : Healthcare, Medical Equipment and Supply, Therapy
Global Neurology Devices Investment Opportunities, Analysis and Forecasts to 2015
- $ 4 000
- May 2009
Global Neurology Devices Investment Opportunities, Analysis and Forecasts to 2015SummaryThis report is an essential source for key information and data relating to the global neurology devices market. The report provides global and country level, detailed and comprehensive coverage of market and cat ...
Industries : Medical Devices, Therapy
World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The
- $ 3 995
- May 2009
Worldwide cancer affects more than 10 million people each year. This number is expected to increase by 2.4% by 2020 to 14 million each year. Worldwide approximately 22 million people are living with cancer and nearly 7 million people die. The most common cancers affecting the world include lung, ...
Industries : Therapy
China Neurology Devices Investment Opportunities, Analysis and Forecasts to 2015
- $ 2 500
- April 2009
China Neurology Devices Investment Opportunities, Analysis and Forecasts to 2015SummaryThis report is an essential source for in-depth information and data relating to China neurology devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and compa ...
Industries : Medical Devices, Therapy
North American Scientific, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
North American Scientific, Inc. - Financial and Strategic Analysis ReviewSummaryNorth American Scientific, Inc. (NAS Medical) manufacture, market and sells products for the treatment of radiation therapy including SurTRAK needles, Prospera brachytherapy seeds and strands that are primarily used in t ...
Industries : Therapy
Alseres Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Alseres Pharmaceuticals, Inc. - Financial and Strategic Analysis ReviewSummaryAlseres Pharmaceuticals, Inc. (Alseres) is a development stage biopharmaceutical company. The company is engaged in the development of drug candidates to diagnose and treat disorders in the central nervous system. It is al ...
Industries : Therapy
Clarient, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Clarient, Inc. - Financial and Strategic Analysis ReviewSummaryClarient, Inc. (Clarient) is a cancer diagnostic company engaged in providing cellular assessment and cancer characterization. The company also provides critical oncology testing services to community pathologists, biopharmaceutical comp ...
Industries : Therapy
Adherex Technologies Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Adherex Technologies Inc. - Financial and Strategic Analysis ReviewSummaryAdherex technologies Inc. (Adherex) is engaged in designing and developing novel cancer therapeutics. It is a biopharmaceutical company focusing on cancer therapeutics. The products of the company are in preclinical and clinic ...
Industries : Therapy
Exelixis, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Exelixis, Inc. - Financial and Strategic Analysis ReviewSummaryExelixis, Inc. (Exelixis) is a biotechnology company focused on development of diversified pharmaceutical products for treatment of cancer and other serious diseases. The company currently has a bouquet of 11 of drug candidates currently ...
Industries : Pharmaceutical, Therapy
Alfacell Corporation - Financial and Strategic Analysis Review
- $ 125
- April 2009
Alfacell Corporation - Financial and Strategic Analysis ReviewSummaryAlfacell Corporation is a biopharmaceutical company engaged in developing drugs for the treatment of cancer and other pathological conditions. It is the first company to develop a biopharmaceutical product candidate that works simi ...
Industries : Pharmaceutical, Therapy
CEL-SCI Corporation - Financial and Strategic Analysis Review
- $ 125
- April 2009
CEL-SCI Corporation - Financial and Strategic Analysis ReviewSummaryCEL-SCI Corporation (CEL-SCI) is a Biotechnology company engaged in the development of drugs for the treatment of cancer and infectious diseases. The company has two product candidate Multikine and L.E.A.P.S. Multikine simulate the ...
Industries : Pharmaceutical, Pathology, Therapy
Introgen Therapeutics, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Introgen Therapeutics, Inc. - Financial and Strategic Analysis ReviewSummaryIntrogen Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of medical therapies for the treatment of cancer and other diseases. The company is developing product pi ...
Industries : Pharmaceutical, Therapy
Advaxis, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Advaxis, Inc. - Financial and Strategic Analysis ReviewSummaryAdvaxis, Inc., (Advaxis) is a development stage Biotechnology Company, engaged in the research and development of new cancer-fighting techniques. It develops cancer vaccines targeting cervical, breast, prostate, ovarian, lung, and other c ...
Industries : Therapy
Infinity Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Infinity Pharmaceuticals, Inc. - Financial and Strategic Analysis ReviewSummaryInfinity Pharmaceuticals, Inc. is engaged in the discovery, development and delivering the best-in-class medicines to patients for the treatment of cancer and related conditions. The company?s programs develop from its in ...
Industries : Therapy
EpiCept Corporation - Financial and Strategic Analysis Review
- $ 125
- April 2009
EpiCept Corporation - Financial and Strategic Analysis ReviewSummaryEpiCept Corporation (EpiCept) is engaged in development and commercialization of novel therapies for the treatment of cancer and pain management. The company focuses on developing compounds to meet the needs of patients in the area ...
Industries : Therapy
Lorus Therapeutics Inc - Financial and Strategic Analysis Review
- $ 125
- April 2009
Lorus Therapeutics Inc - Financial and Strategic Analysis ReviewSummaryLorus Therapeutics, Inc. (Lorus) is a life sciences company is engaged in the discovery, research and development of efficacious and safe anticancer therapies. The company has a varied product pipeline spread across pre-clinical ...
Industries : Therapy
Avalon Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Avalon Pharmaceuticals, Inc. - Financial and Strategic Analysis ReviewSummaryAvalon Pharmaceuticals, Inc (Avalon) is a biopharmaceutical company. The company is principally engaged in the discovery, development and commercialization of first-in-class cancer therapeutics. Its pipeline products includ ...
Industries : Therapy
Curis, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Curis, Inc. - Financial and Strategic Analysis ReviewSummaryCuris, Inc. (Curis) is a drug discovery company engaged in developing medicines in the field of cancer. The company?s development stage products for the treatment of cancer includes GDC-0449, a Phase I expansion cohort; small molecule and a ...
Industries : Therapy
ACADIA Pharmaceuticals Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
ACADIA Pharmaceuticals Inc. - Financial and Strategic Analysis ReviewSummaryAcadia Pharmaceuticals, Inc., (Acadia) engages in the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company focuses on developing a portfolio ...
Industries : Therapy
Bionovo, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Bionovo, Inc. - Financial and Strategic Analysis ReviewSummaryBionovo, Inc. (Bionovo) is a clinical stage company that mainly focuses on developing safe and effective drugs for the treatment of unmet medical needs in women?s health and cancer. It designs new drugs from botanical sources that have no ...
Industries : Therapy
ImClone Systems Incorporated - Financial and Strategic Analysis Review
- $ 125
- April 2009
ImClone Systems Incorporated - Financial and Strategic Analysis ReviewSummaryImClone Systems Incorporated (ImClone) is a company engaged in the research and development of oncology methodologies and therapies. Growth factor blockers and angiogenesis inhibitors are the two key areas where ImClone has ...
Industries : Therapy
Acorda Therapeutics, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Acorda Therapeutics, Inc. - Financial and Strategic Analysis ReviewSummaryAcorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company. It is principally engaged in the identification, development and marketing of novel therapies that are employed in improving neurological func ...
Industries : Therapy
CuraGen Corporation - Financial and Strategic Analysis Review
- $ 125
- April 2009
CuraGen Corporation - Financial and Strategic Analysis ReviewSummaryCuraGen is a biopharmaceutical development company that is focused on the development of novel therapeutics used for the treatment of cancer. Currently, the company concentrates on advancing its cancer treatments namely belinostat a ...
Industries : Therapy
Elan Corporation, plc - Financial and Strategic Analysis Review
- $ 125
- April 2009
Elan Corporation, plc - Financial and Strategic Analysis ReviewSummaryElan Corporation, plc (Elan) is an Irish based biotechnology company, incepted in 1969. The company is focused on the research, development, manufacturing and marketing of advanced therapies in neurology, autoimmune diseases and s ...
Industries : Therapy
Forest Laboratories, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Forest Laboratories, Inc. - Financial and Strategic Analysis ReviewSummaryForest Laboratories, Inc. (Forest Lab) is a U.S. based pharmaceutical company. It is engaged in the development, manufacturing and selling of both branded and generic forms of ethical drug products and over-the-counter product ...
Genta Incorporated - Financial and Strategic Analysis Review
- $ 125
- April 2009
Genta Incorporated - Financial and Strategic Analysis ReviewSummaryGenta Incorporated (Genta) is a biopharmaceutical company engaged in pharmaceutical (drug) research and development. The company focuses on the identification, development and commercialization of drugs for the treatment of cancer an ...
Industries : Therapy
GTx, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
GTx, Inc. - Financial and Strategic Analysis ReviewSummaryGTX, Inc. (GTX) is a biopharmaceutical company engaged in developing bio molecules that target hormone pathways to treat cancer, osteoporosis and bone loss, muscle wasting and other serious medical conditions. The company?s drug discovery pro ...
Industries : Therapy
H Lundbeck AS - Financial and Strategic Analysis Review
- $ 125
- April 2009
H Lundbeck AS - Financial and Strategic Analysis ReviewSummaryH. Lundbeck A/S (Lundbeck) is a pharmaceutical company focused principally on the treatment of diseases of the central nervous system (CNS). The company is having major operations in the U.S. and Europe. In the CNS segment Lundbeck is de ...
Industries : Therapy
ImmunoGen, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
ImmunoGen, Inc. - Financial and Strategic Analysis ReviewSummaryImmunoGen, Inc. (ImmunoGen) is a biopharmaceutical company that is engaged in the development of anticancer product candidates. The company employs tumor-activated product (TAP) technology that involves uses tumor-targeting antibodies f ...
Industries : Therapy
Myriad Genetics, Inc. - Financial and Strategic Analysis Review
- $ 125
- April 2009
Myriad Genetics, Inc. - Financial and Strategic Analysis ReviewSummaryMyriad Genetics, Inc. (Myriad) has its major operations in the development and commercialization of novel therapeutic and molecular diagnostic products. The company principally operates in the U.S. Myriad has main focus on the in ...
Industries : Therapy
reportlinker.com © Copyright 2009. All rights reserved